Loading...
XNAS
INSM
Market cap12bUSD
May 16, Last price  
68.12USD
1D
1.34%
1Q
-14.11%
Jan 2017
414.89%
Name

Insmed Inc

Chart & Performance

D1W1MN
P/E
—
P/S
34.11
EPS
—
Div Yield, %
—
Shrs. gr., 5y
14.17%
Rev. gr., 5y
21.66%
Revenues
364m
+19.17%
131,000991,0007,529,00011,699,00010,373,0006,921,0004,417,000011,500,00011,500,0000009,835,000136,467,000164,413,000188,461,000245,358,000305,208,000363,707,000
Net income
-914m
L+21.91%
-40,929,000-56,139,000-19,962,000-15,667,000118,350,000-6,434,000-59,664,000-41,374,000-56,073,000-79,159,000-118,183,000-176,273,000-192,649,000-324,277,000-254,337,000-294,090,000-434,654,000-481,534,000-749,567,000-913,772,000
CFO
-684m
L+27.53%
-27,765,000-42,204,000-25,255,000-11,992,000-11,012,000-7,722,000-30,205,000-31,012,000-46,664,000-64,416,000-100,700,000-146,708,000-159,617,000-257,977,000-250,649,000-219,348,000-363,302,000-400,439,000-536,247,000-683,882,000
Earnings
Aug 06, 2025

Profile

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
URL
https://insmed.com/
IPO date
Feb 15, 1991
Employees
736
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
363,707
19.17%
305,208
24.39%
245,358
30.19%
Cost of revenue
1,145,225
981,085
718,428
Unusual Expense (Income)
NOPBT
(781,518)
(675,877)
(473,070)
NOPBT Margin
Operating Taxes
3,707
2,555
1,383
Tax Rate
NOPAT
(785,225)
(678,432)
(474,453)
Net income
(913,772)
21.91%
(749,567)
55.66%
(481,534)
10.79%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,084,124
152,475
292,153
BB yield
-9.57%
-3.50%
-11.88%
Debt
Debt current
12,319
10,642
8,126
Long-term debt
111,847
1,242,033
1,222,354
Deferred revenue
Other long-term liabilities
1,375,972
242,779
208,502
Net debt
(1,309,660)
472,228
82,200
Cash flow
Cash from operating activities
(683,882)
(536,247)
(400,439)
CAPEX
(21,923)
(13,288)
(9,878)
Cash from investing activities
(583,175)
(223,604)
(34,584)
Cash from financing activities
1,341,020
168,439
793,273
FCF
(796,421)
(680,736)
(481,019)
Balance
Cash
1,433,826
780,447
1,148,280
Long term investments
Excess cash
1,415,641
765,187
1,136,012
Stockholders' equity
(4,360,412)
(3,445,410)
(2,694,465)
Invested Capital
6,100,434
4,560,260
4,168,783
ROIC
ROCE
EV
Common stock shares outstanding
164,043
140,433
123,035
Price
69.04
122.78%
30.99
55.11%
19.98
-26.65%
Market cap
11,325,529
160.24%
4,352,019
77.04%
2,458,239
-19.51%
EV
10,015,869
4,824,247
2,540,439
EBITDA
(770,505)
(665,298)
(462,739)
EV/EBITDA
Interest
80,258
81,694
26,446
Interest/NOPBT